Emgality (galcanezumab) uses a loading dose because the drug has a long half-life of 27 days, and without that initial double dose, it would take three to four months to build up enough medication in your body to work at full strength. The 240 mg loading dose, given as two back-to-back injections on your first day, pushes your blood levels to the target concentration immediately, so you don’t spend months waiting for the drug to accumulate.
How the Loading Dose Works
Emgality is a monoclonal antibody, a large protein that your body clears slowly. Its elimination half-life is 27 days, meaning it takes nearly a month for your body to remove half of each dose. That slow clearance is why you only need one injection per month for maintenance. But it also means that if you started at the regular 120 mg monthly dose, each injection would add a little more to what’s already circulating, and your blood levels wouldn’t plateau until roughly month three or four.
The 240 mg loading dose shortcuts that buildup. According to the FDA’s clinical pharmacology review, a single 240 mg dose achieves the same steady-state concentration that the 120 mg maintenance dose would eventually reach after months of gradual accumulation. In practical terms, you’re at therapeutic levels from day one instead of waiting a full season.
Why Speed Matters for Migraine Prevention
Emgality works by binding to a protein called CGRP, which plays a central role in triggering migraine attacks. The drug latches onto CGRP molecules floating in your bloodstream and tissues, preventing them from activating pain pathways. It does this with extremely high precision, binding CGRP over 10,000 times more strongly than it binds to similar proteins in the body.
For that blocking effect to be meaningful, you need enough drug circulating to neutralize a significant share of CGRP. A half-dose leaves gaps. The loading dose ensures there’s enough galcanezumab available right away to meaningfully suppress CGRP activity. This is why Eli Lilly introduced the loading dose during phase 3 trials: they expected it to provide a quicker onset of benefit compared to starting low and building up.
The clinical data backed that up. Post-hoc analyses of the two large EVOLVE trials found that patients who received the 240 mg loading dose reported fewer migraine days starting in the very first week. Daily analyses went even further, showing a measurable difference beginning on day one, the first day after the injection. That kind of rapid onset would not be possible if patients started at the lower maintenance dose and waited months to reach full levels.
What the Loading Dose Looks Like in Practice
Your first Emgality appointment for migraine prevention involves two prefilled pens (or syringes), each containing 120 mg, for a combined 240 mg. You inject them one right after the other, in the same session. After that, every subsequent month is a single 120 mg injection.
The injections go under the skin, typically in the thigh, abdomen, or back of the upper arm. Each pen delivers 1 mL of fluid. Some people feel a brief sting or mild pressure at the injection site, but the process takes only seconds per pen.
It’s worth noting that the cluster headache dosing is different. For episodic cluster headache, the dose is 300 mg (three injections of 100 mg each) at the start of a cluster period, then 300 mg monthly until the cluster period ends. There’s no separate “loading” and “maintenance” distinction for cluster headaches because the dose stays the same throughout.
Injection Site Reactions With the Double Dose
Getting two injections at once does slightly increase the chance of a reaction at the injection site compared to a single shot. In the phase 3 trials, about 23% of patients receiving the 240 mg dose reported at least one injection site reaction, compared to 18% at the 120 mg dose and 13% with placebo. These reactions were typically mild: redness, pain, itching, or swelling where the needle went in.
One reassuring finding from a pooled analysis of those trials: injection site reactions did not increase over time with repeated dosing. So while the loading dose day may involve a bit more local irritation simply because you’re getting two shots, that doesn’t set a pattern for future months.
How Emgality Compares to Other CGRP Drugs
Not every CGRP-blocking antibody uses a loading dose. Aimovig (erenumab) and Ajovy (fremanezumab) each have their own dosing strategies based on their unique pharmacokinetics. Emgality’s specific combination of half-life, distribution, and target binding affinity is what makes the loading dose the most efficient path to therapeutic levels. The principle is straightforward: when a drug clears slowly and you need it working now, you front-load it. This is common across many monoclonal antibody therapies, not just migraine drugs.
The tradeoff is minor: one extra injection on your first day, a slightly higher chance of temporary soreness at the injection site, and the cost of an additional pen or syringe for that initial visit. In exchange, you get full migraine-preventive benefit from the start rather than enduring months of subtherapeutic drug levels while the medication slowly builds in your system.